Singular Genomics Systems, Inc. (NASDAQ:OMIC) Shares Acquired by UBS Group AG

UBS Group AG lifted its stake in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC – Get Rating) by 0.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,700,470 shares of the company’s stock after acquiring an additional 25,025 shares during the period. UBS Group AG owned 6.58% of Singular Genomics Systems worth $9,448,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in OMIC. Weil Company Inc. purchased a new position in Singular Genomics Systems during the fourth quarter worth about $107,000. Marquette Asset Management LLC purchased a new position in Singular Genomics Systems during the fourth quarter worth about $73,000. Bank of New York Mellon Corp lifted its position in Singular Genomics Systems by 12.5% during the third quarter. Bank of New York Mellon Corp now owns 149,558 shares of the company’s stock worth $374,000 after buying an additional 16,636 shares during the period. EP Wealth Advisors LLC purchased a new position in Singular Genomics Systems during the third quarter worth about $26,000. Finally, Balyasny Asset Management LLC purchased a new position in Singular Genomics Systems during the third quarter worth about $26,000. Institutional investors and hedge funds own 56.33% of the company’s stock.

Singular Genomics Systems Stock Performance

NASDAQ OMIC opened at $1.12 on Wednesday. The business’s 50-day moving average price is $1.09 and its 200 day moving average price is $1.80. Singular Genomics Systems, Inc. has a twelve month low of $0.76 and a twelve month high of $4.80. The company has a market capitalization of $80.68 million, a PE ratio of -0.87 and a beta of 1.02. The company has a current ratio of 19.73, a quick ratio of 18.36 and a debt-to-equity ratio of 0.04.

Singular Genomics Systems (NASDAQ:OMIC – Get Rating) last released its earnings results on Thursday, March 2nd. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. On average, research analysts predict that Singular Genomics Systems, Inc. will post -1.43 earnings per share for the current year.

Insider Transactions at Singular Genomics Systems

In other news, insider Eli N. Glezer acquired 170,000 shares of the business’s stock in a transaction dated Wednesday, May 17th. The shares were bought at an average cost of $0.82 per share, for a total transaction of $139,400.00. Following the acquisition, the insider now directly owns 4,355,000 shares in the company, valued at approximately $3,571,100. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 22.60% of the company’s stock.

About Singular Genomics Systems

(Get Rating)

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits.